Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
Status:
Terminated
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
Schizophrenia is associated with high rates of cigarette smoking and associated morbidity and
mortality. In this study, smokers with schizophrenia will complete a baseline session and
then randomized to varenicline (VAR) or placebo (PLA). After 1 week on medication,
participants will complete a cigarette rating task session. Participants will then undergo a
72-hr abstinence period in which they will come to the laboratory twice per day and receive
high-value cash reinforcement contingent upon meeting a strict breath CO abstinence
criterion. At each visit, they will rate withdrawal symptoms, mood and craving. At the end of
the abstinence period, they will repeat the cigarette rating task. Participants will return
to the lab to provide a CO sample 24 hours later, and will text the lab with videos of their
CO samples for one week. Date and time of smoking relapse will be measured from these
samples.